Two examples of approved personalized therapy drugs used for CCA therapy are Pemigatinib, which functions as an FGFR2 inhibitor [47], and Ivosidenib, which represents an IDH1 inhibitor [48]. Here, FGFR2 is linked to cholangiocarcinoma.